Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.99M
Average 1.49M
CRVS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $3.7M rose 49.9% year over year, ahead of the +24.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 62.5% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +13.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.7M+62.5% QoQ
- Last fiscal yearDec 2025
- $9.25M+13.3% YoY
- LTMMar 2026
- $10.49M+24.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +49.9% | -100.0% | -149.9 pp |
| 1 year | +13.3% | -100.0% | -113.3 pp |
| 3-year CAGR | +4.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 9.25M USD
- Year-over-year change
- +13.3%
- 4-year CAGR
- -0.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.25M | +13.3% |
| FY2024 | 2024-12-31 | 8.16M | +18.6% |
| FY2023 | 2023-12-31 | 6.88M | -15.0% |
| FY2022 | 2022-12-31 | 8.1M | -14.9% |
| FY2021 | 2021-12-31 | 9.52M | — |
Selling, General & Admin vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.0% is the highest of 9, against a peer median of -7.8%.
- Over three fiscal years its annual growth of +4.5% compares with a peer median of -9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $106M USD | -7.8% | +1.9% | 90.6% | |
| LTM Mar 2026 | $95.58M USD | -30.3% | -20.7% | 203.9% | |
| LTM Jun 2026 | $53.31M USD | -31.2% | -9.4% | 97.7% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $31.1M USD | -1.0% | -11.4% | 87.5% | |
| LTM Mar 2026 | $18.51M USD | +10.2% | +13.1% | — | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| LTM Mar 2026 | $10.49M USD | +24.0% | +4.5% | — | |
| LTM Mar 2026 | $9.36M USD | -6.3% | -5.7% | 12.9% | |
| LTM Jun 2024 | $7.81M USD | — | -15.8% | 957.8% | |
| Peer median (excluding CRVS) | — | -7.8% | -9.4% | 94.1% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 105K |
| Gross Profit | 0 | 0 | 0 | 0 | (105K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.12M | 24.47M | 16.53M | 19.39M | 33.72M |
| Selling, General & Admin | 9.52M | 8.1M | 6.88M | 8.16M | 9.25M |
| Operating Expenses | 38.63M | 32.57M | 23.41M | 27.55M | 42.87M |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| EBITDA | (42.77M) | (40.94M) | (26.88M) | (62.21M) | (15.18M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (38.63M) | (32.57M) | (23.41M) | (27.55M) | (42.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 654K | 1.58M | 1.82M | 2.51M |
| Interest Expense | 15K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.61M) | (8.74M) | (3.62M) | (34.75M) | 27.69M |
| Income Before Tax | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (0.89) | (0.56) | (1.02) | (0.19) |
| EPS (Diluted) | (1.03) | (0.89) | (0.56) | (1.02) | (0.53) |
| Weighted Avg Shares | 41.85M | 46.55M | 48.03M | 60.99M | 78.96M |
| Weighted Avg Shares (Diluted) | 41.85M | 46.55M | 48.03M | 60.99M | 79.74M |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.